At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 533 enrolled
Drug / intervention
Nivolumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Clinical Trial of Nivolumab (BMS-936558) Combined With Ipilimumab Followed by Nivolumab Monotherapy as First-Line Therapy of Subjects With Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma CheckMate 401: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 401
In Brief
A Phase 3 clinical trial evaluating Nivolumab and Ipilimumab for Melanoma. Completed, enrolled 533 participants across 111 sites in 12 countries.
Detailed Summary
The purpose of this study is to determine the effects of combination treatment of Nivolumab with Ipilimumab followed by Nivolumab monotherapy in patients with previously untreated advanced Melanoma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMelanoma
CountriesAustralia, Austria, Belgium, Finland, France, Germany, Ireland, Italy, Norway, Sweden, Switzerland, United Kingdom
Collaborators--
Timeline
Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedNov 2015
Enrollment StartDec 2015
Primary CompletionFeb 2020
TodayJul 2026
First PostedNov 6, 2015
Enrollment StartDec 20, 2015
Primary CompletionFeb 10, 2020
TodayJul 2, 2026
Enrollment to primary: 4.1 yearsPosted 10.7 years ago
Interventions
Nivolumabdrug
Ipilimumabdrug